PILOT AND FEASIBILITY PROGRAM ? RESEARCH STRATEGY The Pilot and Feasibility Program of the Mayo Translational PKD Center (MTPC) is designed to attract new investigators to PKD research. These investigators can be of three different types: (a) PIs with no past or current NIH funding, (b) established PIs with NIH funding but which have not worked in PKD, and (c) PKD- established investigators (rare) with new or innovative ideas or approaches. The P&F Program goal is to provide sufficient funds to generate obtain preliminary data to support applications for research grants from external agencies, especially R and K awards from NIH. Applications submitted in response to the biannual RFA, use a R03-NIH format and are processed through a two-phase review. Phase 1 is the initial PKD- relatedness screening followed by review and ranking of the internal Scientific Review Committee. In Phase 2, the PIs (of top 6-8 ranked proposals) present their work to the External Advisory Committee (EAC) at the annual retreat. The EAC makes the final ranking and recommendation for the 4-funded P&F grants (two pilots from MTPC funds and two pilots from Mayo Clinic cost-share funds). The metrics for success of the P&F program are (a) abstracts and meeting presentations, (b) peer-reviewed publications and (c) external funding. For the initial period of MTPC funding, the Pilot and Feasibility Program enjoyed success by these metrics. From a pool of 37 received proposals, the P&F program funded 11 investigators: 5 new investigators, 5 non- PKD established investigators and one PKD-investigator (new approach, cycle 3). Funding for the 8 pilots completed resulted in 13 peer-reviewed papers, 10 other abstracts and two meeting, oral presentations. These pilot-PIs also submitted 14 national grants resulting in 5 external and two internal grants funded. Together, the P&F program, the selection process and the success-metrics, help to sustain and expand the Center Membership. The current renewal will allow the MTPC Center to expand as well as enrich the already successful Pilot and Feasibility program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK090728-07
Application #
9144765
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
7
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Masyuk, Anatoliy I; Masyuk, Tatyana V; Lorenzo Pisarello, Maria J et al. (2018) Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target. Hepatology 67:1088-1108
Lakhia, Ronak; Yheskel, Matanel; Flaten, Andrea et al. (2018) PPAR? agonist fenofibrate enhances fatty acid ?-oxidation and attenuates polycystic kidney and liver disease in mice. Am J Physiol Renal Physiol 314:F122-F131
Boczek, Nicole J; Hopp, Katharina; Benoit, Lacey et al. (2018) Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants. Eur J Hum Genet 26:1797-1809
Lea, Wendy A; Parnell, Stephen C; Wallace, Darren P et al. (2018) Human-Specific Abnormal Alternative Splicing of Wild-Type PKD1 Induces Premature Termination of Polycystin-1. J Am Soc Nephrol 29:2482-2492
Wong, Annette T Y; Mannix, Carly; Grantham, Jared J et al. (2018) Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 8:e018794
Cornec-Le Gall, Emilie; Torres, Vicente E; Harris, Peter C (2018) Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases. J Am Soc Nephrol 29:13-23
Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier et al. (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 33:477-489
Higashihara, Eiji; Horie, Shigeo; Kinoshita, Moritoshi et al. (2018) A potentially crucial role of the PKD1 C-terminal tail in renal prognosis. Clin Exp Nephrol 22:395-404
Kline, Timothy L; Edwards, Marie E; Garg, Ishan et al. (2018) Quantitative MRI of kidneys in renal disease. Abdom Radiol (NY) 43:629-638
Chebib, Fouad T; Torres, Vicente E (2018) Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 13:1765-1776

Showing the most recent 10 out of 192 publications